Development of a clinical prediction model using integrated epigenetics to predict COVID-19 severity

Abstract Background Epigenetic markers, including DNA methylation (DNAm), can improve early disease diagnosis and risk stratification. The objective of this study was to evaluate whether the inclusion of a DNAm score would improve performance of a clinical prediction model for COVID-19 clinical severity. Methods We performed a retrospective cohort study of adults (>18 years) with COVID-19 who presented to the emergency department from March to June 2020, the initial peak of the COVID-19 epidemic. DNAm scores were performed on a subset of the cohort based upon availability of blood specimens, to characterize epigenetic signatures. Clinical data were obtained from an electronic data warehouse that includes clinical and biological variables. The primary outcome was a modified WHO (mWHO) ordinal score for COVID-19 clinical improvement, which stratifies severity based on respiratory support required. We performed univariate and bivariate analyses to further select variables for inclusion (p<0.05). We used ordinal logistic regression to develop a model predicting mWHO score. DNAm scores were measured at presentation using modified Infinium MethylationEPIC Arrays with 7,831 additional probes targeting 262 immune-enriched genes. We assessed the DNAm score’s incremental impact on predictive model performance, using the estimated logit-hat for the model derived for the entire cohort as an independent variable in a pair of models fit to the DNAm subsample; one with and the other without the score as a variable. The Wald test was used to quantify the incremental predictive value of the DNAm score. Discriminative capacity was quantified and compared using the c-statistic transformation of Somers D. Results A total of 1400 patients were included, 123 with DNAm scores. DNAm score had an adjusted odds ratio of 7.13 (95% CI 1.55-32.85; p=0.01). In comparing models with and without DNAm score, the c-statistic was 0.88 (95% CI 0.82-0.93; p<0.0001) without and 0.90 (95% CI 0.85-0.95; p<0.0001) with the DNAm score, an estimated difference in c-statistic of 0.02 (p=0.14). Conclusion The addition of DNAm scores at presentation improved prediction but not model discrimination in this small sample.

Authors

Institutions

Publication Details

Journal
Human Genomics
Published
2026-07-28
DOI
https://doi.org/10.1186/s40246-026-01017-7
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Development of a clinical prediction model using integrated epigenetics to predict COVID-19 severity

Ivana V. Yang, Iain R. Konigsberg, Janine M. LaSalle, Kathleen C. Barnes et al.
Human Genomics
Epigenetics and DNA Methylation
article

Development of a clinical prediction model using integrated epigenetics to predict COVID-19 severity

Ivana V. Yang, Iain R. Konigsberg, Janine M. LaSalle, Kathleen C. Barnes, Monica Campbell, Andrew A. Monte, Daniel J. Tancredi, James F. Holmes, Michelle Edelmann, Cosby G. Arnold
article en

Abstract

Abstract Background Epigenetic markers, including DNA methylation (DNAm), can improve early disease diagnosis and risk stratification. The objective of this study was to evaluate whether the inclusion of a DNAm score would improve performance of a clinical prediction model for COVID-19 clinical severity. Methods We performed a retrospective cohort study of adults (>18 years) with COVID-19 who presented to the emergency department from March to June 2020, the initial peak of the COVID-19 epidemic. DNAm scores were performed on a subset of the cohort based upon availability of blood specimens, to characterize epigenetic signatures. Clinical data were obtained from an electronic data warehouse that includes clinical and biological variables. The primary outcome was a modified WHO (mWHO) ordinal score for COVID-19 clinical improvement, which stratifies severity based on respiratory support required. We performed univariate and bivariate analyses to further select variables for inclusion (p<0.05). We used ordinal logistic regression to develop a model predicting mWHO score. DNAm scores were measured at presentation using modified Infinium MethylationEPIC Arrays with 7,831 additional probes targeting 262 immune-enriched genes. We assessed the DNAm score’s incremental impact on predictive model performance, using the estimated logit-hat for the model derived for the entire cohort as an independent variable in a pair of models fit to the DNAm subsample; one with and the other without the score as a variable. The Wald test was used to quantify the incremental predictive value of the DNAm score. Discriminative capacity was quantified and compared using the c-statistic transformation of Somers D. Results A total of 1400 patients were included, 123 with DNAm scores. DNAm score had an adjusted odds ratio of 7.13 (95% CI 1.55-32.85; p=0.01). In comparing models with and without DNAm score, the c-statistic was 0.88 (95% CI 0.82-0.93; p<0.0001) without and 0.90 (95% CI 0.85-0.95; p<0.0001) with the DNAm score, an estimated difference in c-statistic of 0.02 (p=0.14). Conclusion The addition of DNAm scores at presentation improved prediction but not model discrimination in this small sample.

Human Genomics
University of California Davis Medical Center (US), University of Colorado Anschutz Medical Campus (US)
Reduced inequalities
Openalex Percentile: Top 14%
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.